JP2010536766A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536766A5
JP2010536766A5 JP2010521080A JP2010521080A JP2010536766A5 JP 2010536766 A5 JP2010536766 A5 JP 2010536766A5 JP 2010521080 A JP2010521080 A JP 2010521080A JP 2010521080 A JP2010521080 A JP 2010521080A JP 2010536766 A5 JP2010536766 A5 JP 2010536766A5
Authority
JP
Japan
Prior art keywords
hydrogen
phenyl
compound according
compound
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010521080A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536766A (ja
JP5385904B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/072049 external-priority patent/WO2009023453A1/en
Publication of JP2010536766A publication Critical patent/JP2010536766A/ja
Publication of JP2010536766A5 publication Critical patent/JP2010536766A5/ja
Application granted granted Critical
Publication of JP5385904B2 publication Critical patent/JP5385904B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010521080A 2007-08-14 2008-08-04 γ−セクレターゼ阻害剤 Expired - Fee Related JP5385904B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95572007P 2007-08-14 2007-08-14
US60/955,720 2007-08-14
PCT/US2008/072049 WO2009023453A1 (en) 2007-08-14 2008-08-04 Azepine derivatives as gamma-secretase inhibitors

Publications (3)

Publication Number Publication Date
JP2010536766A JP2010536766A (ja) 2010-12-02
JP2010536766A5 true JP2010536766A5 (Direct) 2011-09-22
JP5385904B2 JP5385904B2 (ja) 2014-01-08

Family

ID=39811736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521080A Expired - Fee Related JP5385904B2 (ja) 2007-08-14 2008-08-04 γ−セクレターゼ阻害剤

Country Status (11)

Country Link
US (1) US8188069B2 (Direct)
EP (1) EP2178844A1 (Direct)
JP (1) JP5385904B2 (Direct)
KR (1) KR101136260B1 (Direct)
CN (1) CN101778826B (Direct)
AU (1) AU2008287124B2 (Direct)
BR (1) BRPI0815135A2 (Direct)
CA (1) CA2694209C (Direct)
EA (1) EA017286B1 (Direct)
MX (1) MX2010001754A (Direct)
WO (1) WO2009023453A1 (Direct)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
EP2381936B2 (en) 2008-11-24 2020-02-12 Massachusetts Eye & Ear Infirmary Pathways to generate auditory hair cells
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙(氟烷基)-1,4-苯二氮呯酮化合物
WO2013036679A1 (en) * 2011-09-07 2013-03-14 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
WO2014039908A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
JP2015527398A (ja) 2012-09-07 2015-09-17 マサチューセッツ アイ アンド イヤー インファーマリー 聴覚喪失治療
JP2015529251A (ja) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Notch阻害剤としての三環系複素環式化合物
US9273075B2 (en) 2012-09-21 2016-03-01 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
JP2015529253A (ja) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Notch阻害剤としてのフルオロアルキルおよびフルオロシクロアルキル1,4−ベンゾジアゼピノン化合物
JP2015529250A (ja) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company フルオロアルキルジベンゾジアゼピノン化合物
WO2014047392A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
JP2015533811A (ja) 2012-09-21 2015-11-26 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company N−置換ビス(フルオロアルキル)1,4−ベンゾジアゼピノン化合物
CN105308030A (zh) 2012-09-21 2016-02-03 百时美施贵宝公司 烷基、氟烷基-1,4-苯并二氮杂*酮化合物
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥
EP2897944B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
CN105101968A (zh) 2013-04-04 2015-11-25 百时美施贵宝公司 治疗增殖性疾病的组合疗法
WO2015073524A1 (en) * 2013-11-12 2015-05-21 Drexel University Novel methods of treating or preventing alzheimer's disease
US20170314027A1 (en) 2014-08-06 2017-11-02 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
US11370823B2 (en) 2014-10-29 2022-06-28 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
EP3407901B1 (en) 2016-01-29 2021-07-21 Massachusetts Eye & Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
JP6911048B2 (ja) 2016-04-12 2021-07-28 イーライ リリー アンド カンパニー がんの処置において使用するための、Notch阻害剤およびPI3K/mTOR阻害剤を用いた併用療法
CN109310684B (zh) 2016-04-12 2021-11-19 伊莱利利公司 用于治疗癌症的notch和cdk4/6抑制剂的组合疗法
CA3024424A1 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
IL263110B (en) 2016-05-20 2022-07-01 Lilly Co Eli Combined treatment of notch and pd-1 or pd-l1 inhibitors
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
CN110337291A (zh) 2016-12-16 2019-10-15 帕珀莱恩医疗公司 治疗耳蜗突触病变的方法
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
MA50564A (fr) 2017-11-06 2020-09-16 Hutchinson Fred Cancer Res Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
WO2019148067A1 (en) 2018-01-26 2019-08-01 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
IL317554A (en) 2018-06-01 2025-02-01 Novartis Ag Anti-BCMA binding molecules and their uses
KR20220024729A (ko) 2019-06-24 2022-03-03 노파르티스 아게 B-세포 성숙 항원을 표적으로 하는 다중특이성 항체에 대한 투여 요법 및 병용 요법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE421509T1 (de) 1996-12-23 2009-02-15 Elan Pharm Inc Cycloalkyl-, lactam-, lacton- und verwandte verbindungen als hemmer der beta- amyloidpeptidfreisetzung
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) * 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
US7342007B2 (en) * 2003-03-14 2008-03-11 Astrazeneca Ab Lactams and uses thereof

Similar Documents

Publication Publication Date Title
JP2010536766A5 (Direct)
JP2009535462A5 (Direct)
JP2010501534A5 (Direct)
JP2009149903A5 (Direct)
JP2010530897A5 (Direct)
JP2006526031A5 (Direct)
JP2007269812A5 (Direct)
JP2013505929A5 (Direct)
JP2010534247A5 (Direct)
JP2009541403A5 (Direct)
JP2012121931A5 (Direct)
JP2011500769A5 (Direct)
JP2007522220A5 (Direct)
JP2013010749A5 (ja) カルバゾール化合物
JP2011510079A5 (Direct)
JP2007302689A5 (Direct)
JP2011227454A5 (Direct)
JP2007519721A5 (Direct)
JP2010520214A5 (Direct)
JP2014028916A5 (Direct)
JP2014526533A5 (Direct)
JP2010508310A5 (Direct)
JP2010534246A5 (Direct)
JP2010500432A5 (Direct)
JP2010241791A5 (Direct)